We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · August 05, 2021

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Drug Response

Annals of Oncology

 

Additional Info

Annals of Oncology
CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Drug Response: A Secondary Analyses of the KARISMA Trial
Ann. Oncol 2021 Jul 17;[EPub Ahead of Print], W He, M Eriksson, E Eliasson, F Grassmann, M Bäcklund, M Gabrielson, M Hammarström, S Margolin, L Thorén, Y Wengström, S Borgquist, P Hall, K Czene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading